More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

What countries rank the highest and lowest for biopharmaceutical competitiveness? Where are companies investing in research and development and manufacturing, and how do executives assess the competitive landscape for such investment? A recent...
DCAT Value Chain Insights

So what have the been most noteworthy mergers and acquisitions (MA&) thus far in 2015? DCAT Value Chain Insights (VCI) examines the top announced and closed deals thus far and key trends in pharma M&A. Teva's proposed acquisition of...
DCAT Value Chain Insights

The US Food and Drug Administration has approved 14 new molecular entities thus far in 2015. So which are the most promising commercial prospects and what lies ahead for the rest of 2015? DCAT Value Chain Insights (VCI) takes an inside look. As...
DCAT Value Chain Insights

The Drug Supply Chain Security Act (DSCSA) outlines critical steps to build an electronic, interoperable system to identify and trace prescription drugs as they are distributed in the United States. DSCSA has staged implementation over a 10-year...
DCAT Value Chain Insights

A recent report by the US General Accounting Office (GAO) was critical over the lack of coordination between the US Food and Drug Administration (FDA) and the US Drug Enforcement Agency (DEA) for contributing to shortages of controlled substances,...